Cantor Fitzgerald Downgrades Zynerba Pharmaceuticals, Inc. (ZYNE) to Neutral

Cantor Fitzgerald downgraded shares of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) from an overweight rating to a neutral rating in a research note published on Monday, August 7th, Marketbeat reports. The brokerage currently has $4.00 target price on the stock, down from their previous target price of $28.00. Cantor Fitzgerald also issued estimates for Zynerba Pharmaceuticals’ FY2017 earnings at ($2.48) EPS and FY2018 earnings at ($2.41) EPS.

Several other analysts have also recently weighed in on the company. Piper Jaffray Companies cut Zynerba Pharmaceuticals from an overweight rating to a neutral rating and reduced their price target for the stock from $42.00 to $7.00 in a report on Monday, August 7th. Zacks Investment Research cut Zynerba Pharmaceuticals from a hold rating to a sell rating in a report on Friday, August 4th. Maxim Group set a $32.00 price target on Zynerba Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, August 1st. HC Wainwright set a $30.00 price target on Zynerba Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, August 1st. Finally, BidaskClub upgraded Zynerba Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, July 12th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and two have issued a buy rating to the company. Zynerba Pharmaceuticals currently has an average rating of Hold and an average price target of $12.67.

Shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) traded down 1.11% during midday trading on Monday, reaching $6.25. 424,137 shares of the company’s stock were exchanged. The company’s 50 day moving average is $14.21 and its 200-day moving average is $18.65. The stock’s market cap is $82.86 million. Zynerba Pharmaceuticals has a 12 month low of $5.42 and a 12 month high of $25.95.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last released its quarterly earnings results on Tuesday, August 1st. The company reported ($0.64) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by $0.04. Equities analysts forecast that Zynerba Pharmaceuticals will post ($2.45) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Cantor Fitzgerald Downgrades Zynerba Pharmaceuticals, Inc. (ZYNE) to Neutral” was originally posted by BNB Daily and is the sole property of of BNB Daily. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/19/zynerba-pharmaceuticals-inc-zyne-rating-lowered-to-neutral-at-cantor-fitzgerald-updated.html.

A number of institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System acquired a new position in shares of Zynerba Pharmaceuticals during the second quarter valued at about $343,000. The Manufacturers Life Insurance Company purchased a new position in shares of Zynerba Pharmaceuticals during the second quarter worth $158,000. State Street Corp purchased a new position in shares of Zynerba Pharmaceuticals during the second quarter worth $2,698,000. Virtu KCG Holdings LLC purchased a new position in shares of Zynerba Pharmaceuticals during the second quarter worth $535,000. Finally, Parametric Portfolio Associates LLC purchased a new position in shares of Zynerba Pharmaceuticals during the second quarter worth $223,000. 26.74% of the stock is currently owned by hedge funds and other institutional investors.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Analyst Recommendations for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply